UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$950M |
| 2 |
Linde
LIN
|
+$886M |
| 3 |
Amgen
AMGN
|
+$812M |
| 4 |
Pinduoduo
PDD
|
+$400M |
| 5 |
Advanced Micro Devices
AMD
|
+$240M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ametek
AME
|
+$475M |
| 2 |
Microsoft
MSFT
|
+$266M |
| 3 |
Amazon
AMZN
|
+$221M |
| 4 |
VMW
VMware, Inc
VMW
|
+$197M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$140M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.09% |
| 2 | Healthcare | 14.47% |
| 3 | Financials | 11.11% |
| 4 | Consumer Discretionary | 10.49% |
| 5 | Industrials | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2576
Rackspace Technology
RXT
$955M
| $106K | ﹤0.01% |
56,149
| – | – |
|
2577
Vuzix
VUZI
$180M
| $105K | ﹤0.01% |
25,367
-39,274
| -61% | -$177K |
|
2578
Microvast
MVST
$247M
| $101K | ﹤0.01% |
81,793
| – | – |
|
2579
Stoke Therapeutics
STOK
$1.81B
| $94.9K | ﹤0.01% |
+11,398
| New | +$103K |
|
|
KLRS
2580
Kalaris Therapeutics
KLRS
$79.7M
| $93.2K | ﹤0.01% |
+1,029
| New | +$131K |
|
2581
Rimini Street
RMNI
$455M
| $88.4K | ﹤0.01% |
21,459
-35,637
| -62% | -$161K |
|
2582
Energy Vault
NRGV
$471M
| $87.5K | ﹤0.01% |
40,874
| – | – |
|
|
KZR
2583
DELISTED
Kezar Life Sciences
KZR
| $82.1K | ﹤0.01% |
+2,623
| New | +$152K |
|
|
TPC
2584
Tutor Perini Cor
TPC
$4.14B
| $82K | ﹤0.01% |
13,295
-40,449
| -75% | -$326K |
|
2585
Altimmune
ALT
$576M
| $81K | ﹤0.01% |
19,200
-35,500
| -65% | -$422K |
|
2586
ESS Tech
GWH
$21.2M
| $80.3K | ﹤0.01% |
3,852
| – | – |
|
2587
First Trust Rising Dividend Achievers ETF
RDVY
$24.6B
| $77.4K | ﹤0.01% |
+1,725
| New | +$79.2K |
|
2588
Advantage Solutions
ADV
$559M
| $73.8K | ﹤0.01% |
1,869
| – | – |
|
2589
Fulcrum Therapeutics
FULC
$246M
| $73.2K | ﹤0.01% |
25,699
+10,899
| +74% | +$97.7K |
|
|
BLUE
2590
DELISTED
bluebird bio
BLUE
| $69.7K | ﹤0.01% |
1,095
+10
| +0.9% | +$1.14K |
|
|
AEVA
2591
Aeva Technologies
AEVA
$954M
| $66.8K | ﹤0.01% |
11,227
-22,548
| -67% | -$181K |
|
2592
PLAYSTUDIOS Inc
MYPS
$76.7M
| $66.4K | ﹤0.01% |
18,000
-38,419
| -68% | -$156K |
|
|
API
2593
Agora
API
$338M
| $62.6K | ﹤0.01% |
17,300
| – | – |
|
|
TDAY
2594
USA Today Co
TDAY
$1.32B
| $60.8K | ﹤0.01% |
32,488
| – | – |
|
2595
ALX Oncology
ALXO
$261M
| $52.3K | ﹤0.01% |
+11,581
| New | +$87.7K |
|
|
HYZN
2596
DELISTED
Hyzon Motors Inc. Class A Common Stock
HYZN
| $50.7K | ﹤0.01% |
1,244
| – | – |
|
|
FSP
2597
Franklin Street Properties
FSP
$50.3M
| $48.8K | ﹤0.01% |
31,078
| – | – |
|
|
ZH
2598
Zhihu
ZH
$286M
| $36.5K | ﹤0.01% |
4,789
| – | – |
|
2599
ROBO Global Healthcare Technology and Innovation ETF
HTEC
$75.7M
| $35.2K | ﹤0.01% |
+1,180
| New | +$35.5K |
|
|
MAGN
2600
Magnera Corp
MAGN
$488M
| $34.4K | ﹤0.01% |
831
| – | – |
|
Similar funds
UBS AM's Q1 2023 Portfolio in Review
As of Q1 2023, UBS AM held 2,762 positions worth $206B, up 8.3% from $191B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
UBS AM's Q1 2023 filing shows 231 new, 1,328 increased, 856 reduced and 85 closed positions. Its largest new stake was Amgen: 3,308,425 shares worth $800M. The largest sale was Ametek, an estimated $475M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
- UBS AM's largest Q1 2023 buy was Amgen: 3,308,425 shares worth $800M.
- UBS AM added most to Abbott in Q1 2023, an estimated $950M increase.
- UBS AM's biggest Q1 2023 reduction was Ametek, cutting an estimated $475M.
- UBS AM fully exited SVB Financial Group in Q1 2023, selling an estimated $77.3M.
- UBS AM's ten largest holdings make up 22% of its $206B portfolio in Q1 2023.
- UBS AM opened 231 new positions and closed 85 in Q1 2023.
- UBS AM's portfolio value rose 8.3% quarter-over-quarter to $206B.
Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.